Healthcare / Medical DevicesStockholm
$0.11
+0.01 (+4.49%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-7.0M · quality 61.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-96.7%
↓Gross Margin
78.2%
↑Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+33.6%
FCF CAGR
—
FCF margin
-62.6%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.4M · net income $-5.2M · FCF $-4.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.4M | $7.4M | $7.3M | $6.7M | $3.1M |
| Net Income | $-5.2M | $-5.2M | $-7.7M | $-8.5M | $-12.0M |
| EBITDA | $-4.7M | $-4.7M | $-5.9M | $-7.2M | $-11.1M |
| EPS | -0.05 | -0.05 | -0.11 | -0.20 | -0.43 |
| Gross Margin | 78.2% | 78.2% | 77.6% | 77.8% | 78.8% |
| Operating Margin | -67.7% | -67.7% | -86.1% | -122.9% | -384.5% |
| Net Margin | -70.2% | -70.2% | -104.2% | -127.2% | -385.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 1.00 | 0.74 | 0.44 |
| Current Ratio | 1.23 | 1.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.6M | $-4.6M | $-7.7M | $-7.0M | $-13.0M |
| Returns | |||||
| ROE | -96.7% | -96.7% | -177.5% | -165.8% | -222.5% |
| Valuation | |||||
| P/B | 2.32 | 2.32 | 2.72 | 6.37 | 4.35 |
| Growth & Yield | |||||
| Revenue Growth | 0.8% | 0.8% | 9.5% | 116.0% | — |
| EPS Growth | 57.6% | 57.6% | 45.0% | 52.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.05
Residual
-32.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.